Skip to main content

Congenital Fibrinogen Deficiency

What is a congenital fibrinogen deficiency?

Congenital fibrinogen deficiency (CFD) is a rare inherited bleeding disorder that occurs when your body is unable to produce ample fibrinogen (also called Factor I) to help the body form blood clots to stop bleeding. 

CFD is an umbrella term for several related disorders: Afibrinogenemia (a complete lack of fibrinogen), hypofibrinogenemia (low levels of fibrinogen), dysfibrinogenemia (fibrinogen does not work properly), and hypodysfibrinogenemia (a combined defect that involves both low levels of fibrinogen and impaired function). CSL Behring offers fibrinogen replacement therapies to help the body clot properly.

Emily’s Story: How Access to Care Changes Lives

This 13-year-old from Las Vegas is living with congenital afibrinogenemia, an ultra-rare hereditary bleeding disorder that the National Institutes of Health says affects 1 in 1 million newborns. People with the condition can suffer uncontrolled bleeding due to a missing factor in their blood.
Ten years after her family went to Washington, D.C. to successfully advocate for access to care, Emily is living the life of a typical American teen. Hear from Emily and learn more about her journey in this video.

Watch Emily's story

Resources for you

Resource Description  
World Federation of Hemophilia A global organization aiming to improve and sustain care for people with inherited bleeding disorders. View Website
National Hemophilia Foundation A U.S. organization dedicated to finding better treatments and cures for inheritable bleeding disorders. View Website
Hemophilia Federation of America A U.S. nonprofit organization that assists and advocates for the bleeding disorders community. View Website

Treatments Available

Availability of treatments may vary from country to country. Please be sure to visit your local site for further information.

 RiaSTAP® | Fibrinogen Concentrate (Human)

US Prescribing Information

US Important Safety Information(Selected) 

RiaSTAP is contraindicated in patients with known anaphylactic or severe systemic reactions to human plasma-derived products.

Thrombotic events have been reported in patients receiving RiaSTAP. The most common adverse reactions observed in clinical studies (frequency >1%) were fever and headache.

Full US Important Safety Information

 Haemocomplettan P®